US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
CA2341409A1
(en)
*
|
1998-08-31 |
2000-03-09 |
Merck And Co., Inc. |
Novel angiogenesis inhibitors
|
NZ510588A
(en)
*
|
1998-09-18 |
2003-08-29 |
Abbott Gmbh & Co |
Pyrrolopyrimidines as protein kinase inhibitors
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
US6265403B1
(en)
*
|
1999-01-20 |
2001-07-24 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
CZ2002936A3
(cs)
|
1999-09-17 |
2002-10-16 |
Abbott Gmbh & Co. Kg |
Pyrazolopyrimidiny jako terapeutické prostředky
|
HUP0303363A2
(hu)
*
|
1999-09-17 |
2004-07-28 |
Abbott Gmbh & Co., Kg |
Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
US7101869B2
(en)
|
1999-11-30 |
2006-09-05 |
Pfizer Inc. |
2,4-diaminopyrimidine compounds useful as immunosuppressants
|
US7369946B2
(en)
|
2000-03-29 |
2008-05-06 |
Abbott Gmbh & Co. Kg |
Method of identifying inhibitors of Tie-2
|
MXPA02009543A
(es)
*
|
2000-03-29 |
2005-08-26 |
Abbott Gmbh & Co Kg |
Metodo para identificar inhibidores de tie-2.
|
WO2001072751A1
(en)
*
|
2000-03-29 |
2001-10-04 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
KR100403860B1
(ko)
*
|
2000-12-27 |
2003-11-01 |
엘지전자 주식회사 |
차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
AR035885A1
(es)
*
|
2001-05-14 |
2004-07-21 |
Novartis Ag |
Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
|
AP2003002929A0
(en)
*
|
2001-06-23 |
2003-12-31 |
Aventis Pharma Inc |
Pyrrolopyrimidines as protein kinase inhibitors
|
CA2452167A1
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
|
CA2452390A1
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating bone loss
|
DE60216281T2
(de)
|
2001-06-29 |
2007-07-05 |
Ab Science |
Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
|
WO2003002108A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory diseases
|
JP2004537542A
(ja)
*
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
炎症性腸疾患(ibd)を治療するための、チロシンキナーゼ阻害剤の使用
|
US7727731B2
(en)
|
2001-06-29 |
2010-06-01 |
Ab Science |
Potent, selective and non toxic c-kit inhibitors
|
CA2452361A1
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
GB0121033D0
(en)
*
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
US7427623B2
(en)
|
2001-09-11 |
2008-09-23 |
Smithkline Beecham Corporation |
4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
US20030225273A1
(en)
*
|
2002-03-21 |
2003-12-04 |
Michaelides Michael R. |
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
|
BR0313078A
(pt)
|
2002-08-06 |
2005-07-12 |
Astrazeneca Ab |
Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável
|
UA80171C2
(en)
*
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
US20050008640A1
(en)
*
|
2003-04-23 |
2005-01-13 |
Wendy Waegell |
Method of treating transplant rejection
|
US7592352B2
(en)
*
|
2003-05-06 |
2009-09-22 |
Smithkline Beecham Corporation |
Substituted thieno and furo-pyridines
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
JP2007511596A
(ja)
*
|
2003-11-17 |
2007-05-10 |
ファイザー・プロダクツ・インク |
癌の治療において有用なピロロピリミジン化合物
|
EP1730148A4
(en)
*
|
2004-02-03 |
2009-08-19 |
Abbott Lab |
USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
|
GB0403606D0
(en)
*
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
CA2566160C
(en)
*
|
2004-05-27 |
2011-01-18 |
Pfizer Products Inc. |
Pyrrolopyrimidine derivatives useful in cancer treatment
|
WO2006068760A2
(en)
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Anti-inflammatory pyrazolopyrimidines
|
RU2007138264A
(ru)
*
|
2005-03-17 |
2009-09-10 |
Новартис АГ (CH) |
N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
|
KR20080063809A
(ko)
*
|
2005-09-30 |
2008-07-07 |
버텍스 파마슈티칼스 인코포레이티드 |
야누스 키나아제의 억제제로서 유용한 데아자퓨린
|
SI1951724T1
(sl)
*
|
2005-11-17 |
2011-09-30 |
Osi Pharmaceuticals Llc |
Kondenzirani biciklični mTOR inhibitorji
|
US20070135387A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Michaelides Michael R |
Inhibitors of protein kinases
|
WO2007087395A2
(en)
*
|
2006-01-25 |
2007-08-02 |
Osi Pharmaceuticals, Inc. |
UNSATURATED mTOR INHIBITORS
|
AU2007208239B2
(en)
*
|
2006-01-25 |
2013-04-18 |
Synta Pharmaceuticals Corp. |
Substituted aromatic compounds for inflammation and immune-related uses
|
US7585868B2
(en)
*
|
2006-04-04 |
2009-09-08 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
EP2526933B1
(en)
|
2006-09-22 |
2015-02-25 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
EP1969934A1
(de)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
SG10201508035TA
(en)
*
|
2007-03-28 |
2015-10-29 |
Pharmacyclics Inc |
Inhibitors of bruton's tyrosine kinase
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
WO2009088990A1
(en)
|
2008-01-04 |
2009-07-16 |
Intellikine, Inc. |
Certain chemical entities, compositions and methods
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
EP2276763A1
(en)
*
|
2008-03-19 |
2011-01-26 |
OSI Pharmaceuticals, Inc. |
Mtor inhibitor salt forms
|
CN102124009B
(zh)
|
2008-07-08 |
2014-07-23 |
因特利凯公司 |
激酶抑制剂及其使用方法
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
DK2358720T3
(en)
*
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
WO2010129816A2
(en)
|
2009-05-07 |
2010-11-11 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
US7741330B1
(en)
*
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
WO2011146882A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
CA3154024C
(en)
|
2010-06-03 |
2024-02-27 |
Pharmacyclics Llc |
Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
|
EP2637669A4
(en)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and their use
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
FR2970967B1
(fr)
|
2011-01-27 |
2013-02-15 |
Pf Medicament |
Derives de type azaindazole ou diazaindazole comme medicament
|
AR085397A1
(es)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
Combinacion de inhibidores de quinasa y sus usos
|
CA2832291C
(en)
*
|
2011-04-05 |
2015-12-01 |
Pfizer Limited |
Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
|
JP2014520863A
(ja)
|
2011-07-13 |
2014-08-25 |
ファーマサイクリックス,インク. |
Bruton型チロシンキナーゼの阻害剤
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TWI565709B
(zh)
|
2011-07-19 |
2017-01-11 |
英菲尼提製藥股份有限公司 |
雜環化合物及其用途
|
AR091790A1
(es)
|
2011-08-29 |
2015-03-04 |
Infinity Pharmaceuticals Inc |
Derivados de isoquinolin-1-ona y sus usos
|
JP6342805B2
(ja)
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
置換ピラゾロ[3,4−d]ピリミジンおよびその用途
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013166413A2
(en)
*
|
2012-05-03 |
2013-11-07 |
Saint Louis College Of Pharmacy |
Compositions and methods for increasing neurotrophic peptides
|
US9296753B2
(en)
|
2012-06-04 |
2016-03-29 |
Pharmacyclics Llc |
Crystalline forms of a Bruton's tyrosine kinase inhibitor
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
MX2015001081A
(es)
|
2012-07-24 |
2015-10-14 |
Pharmacyclics Inc |
Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
|
EP2689778A1
(en)
*
|
2012-07-27 |
2014-01-29 |
Pierre Fabre Medicament |
Derivatives of azaindoles or diazaindoles for treating pain
|
SG11201502331RA
(en)
|
2012-09-26 |
2015-04-29 |
Univ California |
Modulation of ire1
|
CN104854107A
(zh)
|
2012-11-15 |
2015-08-19 |
药品循环公司 |
作为激酶抑制剂的吡咯并嘧啶化合物
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
CN103333096A
(zh)
*
|
2013-06-25 |
2013-10-02 |
苏州大学 |
一种化学选择性制备多功能吡咯衍生物的新方法
|
SG11201602421VA
(en)
|
2013-09-30 |
2016-04-28 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EA201690713A1
(ru)
|
2013-10-04 |
2016-08-31 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения и их применения
|
CA2943075C
(en)
|
2014-03-19 |
2023-02-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
WO2016022942A1
(en)
|
2014-08-07 |
2016-02-11 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
SG11201707122QA
(en)
|
2015-03-03 |
2017-09-28 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
|
US10550124B2
(en)
|
2015-08-13 |
2020-02-04 |
San Diego State University Foundation |
Atropisomerism for increased kinase inhibitor selectivity
|
NZ740616A
(en)
|
2015-09-14 |
2023-05-26 |
Infinity Pharmaceuticals Inc |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
KR102500416B1
(ko)
*
|
2016-06-21 |
2023-02-17 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체
|
CN109640999A
(zh)
|
2016-06-24 |
2019-04-16 |
无限药品股份有限公司 |
组合疗法
|
PT3612519T
(pt)
|
2017-04-18 |
2022-02-22 |
Lilly Co Eli |
Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
|
US20210253585A1
(en)
*
|
2018-08-22 |
2021-08-19 |
Jiangsu Hengrui Medicine Co., Ltd. |
Preparation method of pyrrolo-amino-pyridazinone compound and intermediate thereof
|
US20220169642A1
(en)
*
|
2019-04-10 |
2022-06-02 |
Cellestia Biotech Ag |
Compounds for the treatment of oncovirus induced cancer and methods of use thereof
|
SG11202111327XA
(en)
|
2019-05-13 |
2021-11-29 |
Relay Therapeutics Inc |
Fgfr inhibitors and methods of use thereof
|
CN110483523B
(zh)
*
|
2019-08-27 |
2022-11-22 |
药雅科技(上海)有限公司 |
一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
|
CN114710956A
(zh)
*
|
2019-08-29 |
2022-07-05 |
希伯塞尔股份有限公司 |
抑制perk的吡咯并嘧啶化合物
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
WO2021184154A1
(en)
|
2020-03-16 |
2021-09-23 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
IL302807A
(en)
|
2020-11-18 |
2023-07-01 |
Deciphera Pharmaceuticals Llc |
GCN2 and PERK kinase inhibitors and methods of using them
|
TW202233625A
(zh)
*
|
2020-11-18 |
2022-09-01 |
美商傳達治療有限公司 |
Fgfr抑制劑及其製造及使用方法
|
AU2022350571A1
(en)
*
|
2021-09-23 |
2024-05-09 |
3H (Suzhou) Pharmaceuticals Co., Ltd. |
Fgfr inhibitors and methods of use thereof
|
WO2023104035A1
(zh)
*
|
2021-12-06 |
2023-06-15 |
英矽智能科技(上海)有限公司 |
取代的单环或双环杂环化合物,其制法与医药上的用途
|
WO2023202625A1
(zh)
*
|
2022-04-20 |
2023-10-26 |
深圳福沃药业有限公司 |
Fgfr2抑制剂及使用方法
|